Loading…

Evaluation of the effects of MERCK, MODERNA, PFIZER/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: A metadata analysis

This research investigates the impact of four specific vaccines on the health of people who have been vaccinated. The vaccines under scrutiny are MERCK, MODERNA, PFIZER BioNTech, and JANSSEN. The analysis considers a range of variables, including symptoms, mortality status, gender, age, number of va...

Full description

Saved in:
Bibliographic Details
Published in:Informatics in medicine unlocked 2024, Vol.49, p.101564, Article 101564
Main Authors: Al-Rousan, Nadia, Al-Najjar, Hazem
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This research investigates the impact of four specific vaccines on the health of people who have been vaccinated. The vaccines under scrutiny are MERCK, MODERNA, PFIZER BioNTech, and JANSSEN. The analysis considers a range of variables, including symptoms, mortality status, gender, age, number of vaccine doses, hospitalization status, and the number of days following vaccination. The methodology involves cross-tabulation analysis to establish connections between vaccinated individuals and the variables under examination. The dataset was compiled from the Centers for Disease Control and Prevention, encompassing roughly 65,000 cases and documenting over 40 distinct symptoms. The overall mortality rate among the vaccinated population is noteworthy. Notably, 40 different mild to severe symptoms were reported among vaccinated individuals. The research highlights the 10 most common symptoms experienced after vaccination. Females under 60 years of age constitute the majority of the dataset. The vaccination-related mortality rate stands at approximately 3 % of those who received the vaccine, with the majority of cases occurring among individuals under the age of 60, who were not hospitalized and had received their initial vaccine dose.
ISSN:2352-9148
2352-9148
DOI:10.1016/j.imu.2024.101564